皓元医药公告，股东苏民投君信（上海）产业升级与科技创新股权投资合伙企业（有限合伙）持股 690.94万股，占3.26%；因资金需求，拟于2025年8月29日～2025年11月28日，通过集中竞价减持不超过 212.1万股，占1%，通过大宗交易减持不超过424.2万股，占2%，合计减持不超636.3万股，占3.00%。 ...

Group 1: Aojie Technology - Aojie Technology has made significant progress in ASIC business, RedCap chips, and 4G/5G smartphone chips [1] - The ASIC business is focused on smart wearables, edge SOC, RISC-V, and cloud inference chips, with expected substantial revenue growth by 2026 [1] - RedCap chips are commercially available in the IoT market, and the company has production capabilities in the smart wearable market [1] - The company has successfully commercialized 4G quad-core chips and is making steady progress in the development of 4G octa-core, 6nm 4G octa-core, and 6nm 5G octa-core chips [1] - Aojie Technology plans to control the growth of operating and R&D expenses to no more than 15% and has no plans for convertible bond issuance or Hong Kong listing [1] Group 2: Haoyuan Pharmaceutical - Haoyuan Pharmaceutical is committed to a global development strategy, with international business revenue expected to account for nearly 40% in 2024 [1] - The company has established collaborations with multinational pharmaceutical giants, universities, research institutes, and CROs [1] - The net operating cash flow is projected to turn positive to 380 million yuan in 2024, with continued focus on cash flow management in 2025 [1] - The company has a strong presence in the ADC field, with the Chongqing ADC CDMO factory providing one-stop services [1] - Haoyuan Pharmaceutical emphasizes ESG practices, having established an ESG governance framework and received multiple ESG awards [1] Group 3: Chongda Technology - Chongda Technology anticipates positive growth in the global PCB market by 2025, with strong order demand and rising product prices [2] - The company's capacity utilization rate is at 85%, with new production capacities being added in Zhuhai and Thailand [2] - To improve profitability, Chongda Technology is focusing on high-value customers, optimizing sales structure, and enhancing cost management [2] - The company is implementing a structural price increase strategy to address rising raw material costs [2] - The U.S. market accounts for 10% of the company's revenue, and it is adopting strategies to diversify markets and optimize customer cooperation in response to tariff policy changes [2]

Core Points - The company announced the results of the second vesting period for its 2023 restricted stock incentive plan, with 527,660 shares to be listed on August 6, 2025, representing 0.25% of the company's total share capital before vesting [2][3][4] Group 1: Stock Incentive Plan Details - The stock listing type is for equity incentive shares, with a total of 527,660 shares to be listed [2][3] - The decision-making process for the stock vesting was approved by the board and supervisory committee on June 26, 2023, and the plan was publicly disclosed on June 27, 2023 [4][5][6] - The number of individuals eligible for the stock vesting is 97, with the actual number of shares vesting being 527,660 [12][13] Group 2: Stock Listing and Capital Changes - The listing date for the vested shares is set for August 6, 2025, and the total share capital will increase from 211,571,033 shares to 212,098,693 shares [14][17] - The company received a total of RMB 11,904,009.60 from the 97 participants in the stock incentive plan, which includes an increase in share capital of RMB 527,660 [17] - The impact of the new shares on the company's financial report is minimal, with the diluted earnings per share remaining stable [18] Group 3: Convertible Bond Adjustments - The company announced an adjustment to the conversion price of its convertible bonds ("Hao Yuan Convertible Bonds") due to the completion of the stock vesting [19][20] - The conversion price was adjusted from RMB 40.59 to RMB 40.55 per share, effective from August 5, 2025 [23][26] - The adjustment was made in accordance with the company's regulations and relevant laws, ensuring the protection of bondholders' rights [24][25]

Core Viewpoint - The announcement details the results of the second vesting period of the 2023 restricted stock incentive plan for Shanghai Haoyuan Pharmaceutical Co., Ltd, including the number of shares to be listed and the relevant procedures for vesting and stock issuance [1][2][3]. Group 1: Stock Listing and Vesting Details - The total number of shares to be listed for trading is 527,660 shares, with the listing date set for August 6, 2025 [1][12]. - The second vesting period for the restricted stock was completed on July 31, 2025, and the company has received the necessary registration proof from the Shanghai branch of China Securities Depository and Clearing Corporation [1][11]. - The total number of shares vested in this period is 52.7660 million shares, which represents 50% of the total granted shares [8]. Group 2: Decision-Making Process - The decision-making process for the vesting involved multiple meetings, including the board of directors and the supervisory board, which approved the relevant proposals regarding the incentive plan [2][4]. - The independent directors provided their consent to the proposals related to the 2023 incentive plan [2][4]. - The company conducted an internal public notice regarding the list of proposed incentive recipients, with no objections received during the notice period [3]. Group 3: Financial Impact and Share Capital Changes - Following the vesting, the total share capital of the company increased from 211,571,033 shares to 212,098,693 shares [9][11]. - The company reported a net profit attributable to shareholders of 62,384,400.02 yuan for the first quarter of 2025, with basic earnings per share of 0.30 yuan per share [11]. - The new shares will dilute the earnings per share based on the increased total share capital while keeping the net profit unchanged [11].

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-097 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于 2023 年限制性股票激励计划第二类限制性股票 第二个归属期归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 527,660股。占归属前公司股本总额的 0.25%。 本次股票上市流通总数为527,660股。 本次股票上市流通日期为2025 年 8 月 6 日。 根据中国证监会、上海证券交易所、中国证券登记结算有限责任公司上海分 公司有关业务规则的规定，上海皓元医药股份有限公司（以下简称"公司"）2023 年限制性股票激励计划第二类限制性股票第二个归属期于 2025 年 7 月 31 日完成 归属登记手续，已收到中国证券登记结算有限责任公司上海分公司出具的《证券 变更登记证明》。现将有关情况公告如下： 一、本 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-098 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于调整可转换公司债券"皓元转债"转股价格暨 转股停复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因公司 2023 年限制性股票激励计划第二类限制性股票完成归属导致"皓元转 债"转股价格调整,本公司的相关证券停复牌情况如下： | | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | 皓元转债 | 可转债转股停 牌 | 2025/8/4 | 全天 | 2025/8/4 | 2025/8/5 | | 证券代码 118051 | | | | | | | 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特定 对象发行可转换公司 ...

证券之星消息，7月30日医疗服务板块较上一交易日下跌1.45%，皓元医药领跌。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301096 | 百诚医药 | 54.58 | 7.65% | 11.38万 | | 6.09亿 | | 688710 | 益诺思 | 46.53 | 3.86% | 5.10万 | | 2.36亿 | | 300683 | 海特生物 | 51.98 | 2.71% | 17.99万 | | 8.88亿 | | 600721 | 自化医药 | 8.48 | 2.17% | 48.33万 | | 4.09亿 | | 300404 | 博济医药 | 11.20 | 1.17% | 47.49万 | | 5.34亿 | | 300149 | 睿智医药 | 13.75 | 1.03% | 163.19万 | | 23.44亿 | | 0 ...

CRO概念板块短线走低，皓元医药跌超10%，药石科技、海特生物、昭衍新药、凯莱英等跟跌。 ...

Core Viewpoint - Shanghai Haoyuan Pharmaceutical Co., Ltd. has decided not to exercise the early redemption rights for its convertible bonds, "Haoyuan Convertible Bonds," despite meeting the conditions for redemption, to protect investor interests and demonstrate confidence in the company's long-term development and intrinsic value [2][12]. Group 1: Convertible Bond Issuance and Redemption - The company issued 8.2235 million convertible bonds with a total amount of 822.35 million yuan, with a maturity of 6 years [3]. - The bonds were listed on the Shanghai Stock Exchange on December 19, 2024, under the code "118051" [4]. - The initial conversion price was set at 40.73 yuan per share, later adjusted to 40.58 yuan and then to 40.59 yuan due to corporate actions [5][8]. Group 2: Redemption Conditions and Triggering Events - The redemption clause allows the company to redeem the bonds if the stock price exceeds 130% of the conversion price for at least 15 out of 30 consecutive trading days [9][11]. - From July 8 to July 29, 2025, the stock price met the redemption condition, triggering the right to redeem the bonds [11]. Group 3: Board Decision and Future Considerations - The board of directors convened on July 29, 2025, and unanimously decided not to exercise the early redemption rights for the bonds [12]. - The company will not exercise the redemption rights for the next three months, and if the redemption conditions are met again after October 30, 2025, the board will reassess the situation [12][17]. Group 4: Related Party Transactions - During the six months prior to the redemption condition being met, there were no transactions of the convertible bonds by major shareholders and executives, ensuring compliance with regulations [13][14]. Group 5: Compliance and Verification - The sponsoring institution confirmed that the decision not to redeem the bonds was approved by the board and complied with relevant regulations and guidelines [15][16].

Core Insights - The Chinese pharmaceutical industry is experiencing a resurgence after three years of stagnation, driven by high-value licensing deals from multinational pharmaceutical companies [1][2] - There is a significant interest from overseas investors in Chinese biopharmaceutical companies, with a notable increase in licensing agreements and IPO activities [2][8] - The trend of "licensing out" Chinese drug candidates to foreign companies is becoming more common, providing Chinese firms with milestone payments and a share of sales revenue [4][6] Group 1: Market Dynamics - As of mid-July, approximately 288 companies are waiting for IPOs in Hong Kong, many of which are biopharmaceutical firms seeking to list under the 18A rule [1][8] - The Hong Kong medical sector has seen a 54% increase this year, significantly outperforming the MSCI China Index, which rose by 17% [8] - The average price-to-earnings (PE) ratio for the sector is around 30 times, placing it in the 15th percentile of its valuation range over the past five years [8] Group 2: Investment Trends - U.S. investment banks are playing a crucial role in facilitating these licensing deals and IPOs, with cornerstone investors contributing 42% of IPO financing this year, two-thirds of which comes from overseas [1][12] - The trend of U.S. pharmaceutical companies seeking to lower costs through partnerships with Chinese firms is expected to continue, especially in light of U.S. drug pricing policies [2][6] Group 3: Licensing Agreements - The number of licensing transactions from China has increased significantly, with 35 deals in 2023 and projected to reach 43 in 2024, alongside a total upfront payment of $2.957 billion in 2023 [3][6] - Notable licensing agreements include Akeso's ivonescimab, which was licensed to Summit Therapeutics for a total value of $5 billion, marking one of the largest overseas licensing deals in Chinese biopharmaceutical history [7][6] Group 4: Future Outlook - Chinese biopharmaceutical companies are increasingly able to produce globally recognized clinical data, particularly in competitive fields like oncology and immunology [2][6] - The shift from merely selling drug pipelines to achieving global commercialization is essential for the future growth of Chinese pharmaceutical companies [13][15] - There is a need for Chinese firms to enhance their innovation capabilities and international execution to compete effectively on a global scale [14][15]